Truffle Capital has raised €250m ($278m) million for a new medtech dedicated fund. The French VC firm said its BioMedTech fund will be used to launch 12 medtech companies, based on disruptive technologies from the top 50 US and European universities.
Truffle Capital CEO and co-founder, Philippe Pouletty told Medtech Insight the new financing would mostly go to French start-ups with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?